ERUCOV-VAC
ERUCOV-VAC is a COVID-19 vaccine candidate developed by Health Institutes of Turkey and Erciyes University.[1][2]
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Routes of administration | Intramuscular |
ReferencesEdit
- ^ "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 21 March 2021.
- ^ "Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19". clinicaltrials.gov. United States National Library of Medicine. Retrieved 4 April 2021.
| Scholia has a profile for ERUCOV-VAC (Q106532118). |
.png){kind=small} | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |